Navigation

    Forum

    • Register
    • Login
    • Search
    • Categories
    • Recent
    • Popular
    • Users
    • Groups
    1. Home
    2. Popular
    Log in to post
    • All categories
    • About
    • Announcements
    • Tours
    • PAAB Forum Tutorials
    • Newsletters/Blogs
    • PAAB Code
    • Events & Training
    •      Session 2 of PAAB Remote Training - Banner Ads
    •          Pre-Session Questions
    •      Session 3 of PAAB Remote Training - Digital Conferences
    •          Pre-Session Questions
    • Resources
    •      Guidance on Code Application
    •      Guidance on Submission Procedures
    •      Guidance on DTCA / DTCI Regulations
    •      Newsletters
    •      PAAB Icons
    •      Activities
    •      External Resources
    •      PAAB Logo
    • PAAB Q&A
    •      Claims & Support/References for Claims
    •      Non-product branded APS, pre-NOC teasers
    •      NHP, OTC
    •      CME, educational material, Reprints, reports, textbooks, independently created content
    •      DTCA/I, consumer secondary audience
    •      Electronic Media
    •      FYI post-approval change/preclearance exemption/what requires review/PAAB scope
    •      Miscellaneous
    •      Disclosure requirements: PI & Safety Information, Federal schedule, study parameters, reference lists
    •      Giveaways, Incentives & GIfts, contests, coupons (maybe activities)
    •      International Conferences
    •      Linkage Issues
    •      Patient Info
    •      Press Releases, Financial Reports, Unsolicited Requests
    •      Sampling
    •      Submission Requirements/process & Timelines/eFiles
    •      Terms of Market Authorization
    •      Visuals/Layout
    • All Topics
    • New Topics
    • Watched Topics
    • Unreplied Topics
    • All Time
    • Day
    • Week
    • Month
    • Jennifer Carroll

      Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context.
      Newsletters/Blogs • • Jennifer Carroll

      32
      3
      Votes
      32
      Posts
      616
      Views

      Jennifer Carroll

      Good Morning @tmcd,

      The rest of the sentence quoted above reads “discussion of disease content would suggest the therapeutic use without properly limiting to the specifics of the products indication.”. The copy “arthritis” is discussion of the disease which suggests the therapeutic use.

      Any HCP product advertising that identifies a disease must, disclose which patients the product can actually be considered in. In the hypothetical example, the product is not for anyone who has arthritis. The presence of the indication consequently triggers the need for the lowest level fair balance statement.

      As noted above, "Drug X efficacy profile" (without mention of the disease/condition) would NOT trigger the above requirements.

    • Jennifer Carroll

      NEW PAAB Logo Revealed
      Announcements • • Jennifer Carroll

      11
      2
      Votes
      11
      Posts
      223
      Views

      palanski

      @Jennifer-Carroll I've solicited feedback from ANTIBODY's Creative Director, Melisa Barrilli, who had the following thoughts to offer on the bilingual logo:

      Although we rarely use bilingual logos, they do come in handy. Glad a version was created! The bilingual logo seems to have optimized the space and flows well. Legibility seems excellent for the PAAB/CCPP words. It will be interesting to see how all versions look when applied at their minimum recommended size—there's considerable size variation with the smaller type, so "Reviewed by" may become illegible if used too small.

      Hope this is useful!

    • Jennifer Carroll

      PAAB Logo Style Guide
      PAAB Logo • • Jennifer Carroll

      9
      0
      Votes
      9
      Posts
      548
      Views

      Jennifer Carroll

      Hello @ABrown

      No. The approval period will remain the same with the understanding that pieces will be updated accordingly. For example, if pieces have already been printed and the renewal is to use up printed stock. The manufacturer should be taking the update into consideration now and printing pieces accordingly.

      If the piece is unaffected and meets the criteria outlined in the previous response above in this thread, it would not prompt the replacement of the PAAB logo prior to acceptance. Please note that it is still encouraged that the piece be updated if there are no reasons for it to remain with the old logo (i.e. using up excess printed stock).

    • Jennifer Carroll

      Clarification on Logo Sizing
      PAAB Logo • • Jennifer Carroll

      7
      0
      Votes
      7
      Posts
      614
      Views

      Jennifer Carroll

      Great question @rebeccaallen

      For simplicity, we have constructed the chart below:

    • T

      pre-NOC and post NOC disease state APS
      Non-product branded APS, pre-NOC teasers • • turnapage

      5
      0
      Votes
      5
      Posts
      479
      Views

      T

      @jennifer-carroll Thank you for your help

    • K

      Mention of new indication in 1x1 email to HCP
      PAAB Q&A • • karen.taylor

      5
      0
      Votes
      5
      Posts
      78
      Views

      K

      Thank you @Jennifer-Carroll. Appreciate the additional clarification. Helps to have this in writing for alignment across various stakeholders.

    • L

      COVID-19 Question Responses
      Claims & Support/References for Claims • • lilymcneil

      4
      0
      Votes
      4
      Posts
      88
      Views

      Jennifer Carroll

      @lilymcneil

      These questions may be acceptable if the content, context, and link aligns with the general guidance provided in our prior response. Of course, copy specific guidance would be provided as part of the review process. Questions and responses need to be assessed in the context of the entire piece and with assessment of the references.

    • S

      COVID-19 Patient Support Program
      Miscellaneous • • SKW

      4
      0
      Votes
      4
      Posts
      91
      Views

      Jennifer Carroll

      @SKW

      If independent third party content on COVID-19 is being provided to a patient through a branded patient support program, an assessment of the linkage should be performed to ensure the acceptability of the content within the context of the brand. This remains true even if being sent without the brand logo (i.e. they are being sent the content because they are part of the branded patient support program). PAAB would do an assessment of the linkage to the content which could be done through an opinion file and would be subject to the four day turn around time.

    • A

      Generic product launch announcement: can we mention the original brand name?
      Claims & Support/References for Claims • • akar

      4
      0
      Votes
      4
      Posts
      50
      Views

      Jennifer Carroll

      @akar Great question.

      Note that any of the proposed content would require review under the PAAB code. This is occasionally a point of confusion in the generic space.

      If the generic product’s TMA refers to the innovator brand as the reference product, the generic manufacturer may convey this fact in the APS. For example, “… generic version of Drug X [the reference product]”.

      In the unlikely event that the reference product is no longer authorized for sale, this should be conveyed through a cross-reference to the claim above. However, a manufacturer should only discuss the availability status of its own products. For example, it would be unacceptable to comment on a competitor’s drug shortage issues.

      Any messages relating to switching will require support from the TMA or standard setting organizations.

    • Jennifer Carroll

      497 - I would appreciation clarification of Section 6.6 of the code related to patient information direct from and consistent with the Product Monograph in combination with gating requirements. If a video is created that walks a patient through how to administer the injection as per part III, does not mention what the product is used for, and that video is posted (with no gating) on the company's website right below the product monograph for that product (as you know companies typically have a page on their company site with all their product monographs posted)......is 1) that video exempt from PAAB review and 2) Can the video be left ungated in this situation (i.e. Does proximity to the monograph pose an issue)? Thank you.
      Patient Info • • Jennifer Carroll

      3
      0
      Votes
      3
      Posts
      33
      Views

      Jennifer Carroll

      Hey @NatBourre
      We have not received a response at this time. We will reach out to Health Canada to see what the status of this question is. In the interim, we will continue to apply our understanding that this cannot been done as this would contravene consumer regulations.

    • Jennifer Carroll

      401 - Is there a PAAB mandate anywhere that states that the pharmaceutical companies corporate logo has to appear on all PAAB reviewed and approved APS materials? We have a situation there are high-priority approved APS materials requiring printing; however the corporate branding is changing and won’t be fully established for some time.
      Miscellaneous • • Jennifer Carroll

      3
      0
      Votes
      3
      Posts
      18
      Views

      Jennifer Carroll

      Hi @NatBourre, the distinction is “company logo” versus “company name”. The code does not require a company logo. However, the company name is required on all pieces unless it contravenes other regulations, such as help-seeking messages. The distinction between “logo” and “name” was particularly relevant to the question as it featured concerns about displaying the corporate logo in the midst of a corporate branding change.

    • C

      Unadjusted p-values
      Claims & Support/References for Claims • statistics multiplicity unadjusted • • COREkarentaylor

      3
      0
      Votes
      3
      Posts
      64
      Views

      C

      Thanks @Jennifer-Carroll!

    • A

      PAAB Exemption
      FYI post-approval change/preclearance exemption/what requires review/PAAB scope • • akar

      3
      0
      Votes
      3
      Posts
      34
      Views

      Jennifer Carroll

      Hey @akar

      The Distinction Between Advertising and Other Activities, the Health Canada document which outlines what constitutes advertising, asks a series of questions to determine the nature of the activity. The author and distributor being a medical director in and of itself, does not, in and of itself, necessarily render a piece exempt from Federal advertising regulations, the PAAB Code, or PAAB preclearance. Please see PAAB Q&A 403. While this question asks about “slides”, the same would apply to letters, emails, etc.

      PAAB Q&A 750 also walks through a similar set of questions to ask about the activity.

      A letter stating only that the sponsor’s product is available would be exempt from preclearance regardless of the source within the company. But it should be noted that certain industry association Codes do not permit such promotional materials to be signed by Medical/Scientific personnel.

      Similarly, a letter only indicating that the sponsor’s product is not available would also be exempt. However, in my experience, when such a letter is signed-off by medical/scientific personnel, it’s because the letter goes beyond that simple message (e.g., why the shortage exists, when the shortage is expected to be resolved, what is being done to mitigate the shortage, what prescribers can consider in the meantime, or so on). Anything on this matter beyond the fact that the product is available or unavailable would require preclearance.

      If you are unsure if the activity would be considered advertising, and if that advertising requires review, please submit a request for a written opinion (see fee schedule on the PAAB website).

    • J

      There are a lot of clinical trials underway on Medical Cannabis. If some of these trials are successful and Medical Cannabis companies can start making claims will they be required to submit their APS's to PAAB?
      Miscellaneous • • Jeff Kent

      3
      0
      Votes
      3
      Posts
      45
      Views

      J

      @Jennifer-Carroll said in There are a lot of clinical trials underway on Medical Cannabis. If some of these trials are successful and Medical Cannabis companies can start making claims will they be required to submit their APS's to PAAB?:

      Medical cannabis is a healthcare product. Healthcare professional (HCP) advertising for medical cannabis therefore falls within the scope of the PAAB Code of Advertising Acceptance. Currently, medical cannabis advertising may not contain claims, even when directed to healthcare professionals. Advertising materials that do not contain claims are exempt from preclearance for any product category (excluding opioids).
      However, specific medical cannabis products that are granted a form of Terms of Market Authorization (TMA) based on evidence relating to particular therapeutic uses will presumably be permitted to make claims in HCP advertising. Of course, those materials would exceed the exemption criteria outlined in the PAAB code and would not be exempt from preclearance.

      Thanks Jennifer - this is very informative. We will share this with our customers.

    • G

      Linking out to RAMQ website
      FYI post-approval change/preclearance exemption/what requires review/PAAB scope • • gbrl88

      3
      0
      Votes
      3
      Posts
      53
      Views

      G

      @Jennifer-Carroll said in Linking out to RAMQ website:

      A link to the formulary site for any province would render the piece subject to review. While a message of “now on formulary” may be considered exempt and the formulary alone is not within the scope of the PAAB code, the linking of the two pieces renders the content subject to the advertising provisions as it creates a link between the brand and a therapeutic message. As per PAAB Q&A 565, the link to RAMQ coverage would be considered a therapeutic link. Hope that helps.

      Thank you for clarifying Jennifer!

    • R

      Unbranded emails with corporate attachments
      PAAB Q&A • • rcolbear

      3
      0
      Votes
      3
      Posts
      46
      Views

      Jennifer Carroll

      Hey @rcolbear

      Yes, the entirety of the message delivered should meet the standards of code section 1.5E in order to not be subject to PAAB preclearance.

    • T

      Pre NOC Communications
      Non-product branded APS, pre-NOC teasers • • turnapage

      3
      0
      Votes
      3
      Posts
      73
      Views

      T

      @jennifer-carroll Thank you very much for the advice.

    • Jennifer Carroll

      137 - Would there be an issue with an online banner ad that is exempt from PAAB review linking through to a PDF of the products' Product Monograph?
      DTCA/I, consumer secondary audience • • Jennifer Carroll

      3
      1
      Votes
      3
      Posts
      34
      Views

      Jennifer Carroll

      @NatBourre Good catch. The hyperlink was an error. We have revised the content now. Thank you.

    • A

      Guidance Document for Reporting Claims in Relative Terms (RRR)
      Guidance on Code Application • • admin

      3
      0
      Votes
      3
      Posts
      621
      Views

      Jennifer Carroll

      Hey @palanski and team

      You are correct. Relative claims may appear as the main message (headline), when they include the absolute values. These should be presented as an integral part of the claim and should NOT be a different colour, style, size etc. All other aspects (quantification and qualification) you would normally include in the claim, still remain applicable.

    • Jennifer Carroll

      PAAB Logo Style Guidelines are posted.
      Announcements • • Jennifer Carroll

      3
      0
      Votes
      3
      Posts
      37
      Views

      Jennifer Carroll

      Thanks for identifying that @palanski !

      We've adjusted the privileges so that you should now have access.